Clinical Trials Logo

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.


Clinical Trial Description

The primary purpose of this study is to demonstrate that treatment with ABT-450/ritonavir (r)/ABT-267 and ABT-333 administered with or without ribavirin (RBV) has non-inferior efficacy compared to treatment with telaprevir and pegylated interferon alpha-2a (pegIFN) and RBV and to compare the safety of these regimens in treatment-naive hepatitis C virus (HCV) genotype (GT) 1a- and 1b-infected adults. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01854697
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date March 2013
Completion date July 2015

See also
  Status Clinical Trial Phase
Completed NCT02216422 - A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection Phase 3
Completed NCT02219503 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Phase 3
Completed NCT01700179 - Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants Phase 1
Completed NCT02486406 - A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Phase 2/Phase 3
Completed NCT01704755 - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Phase 3
Completed NCT01225380 - A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Phase 2
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Completed NCT02065999 - Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Completed NCT01715415 - A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults Phase 3
Completed NCT01716585 - A Study to Evaluate Chronic Hepatitis C Infection Phase 3
Completed NCT01453075 - Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) Phase 1
Completed NCT01011166 - Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) Phase 2
Completed NCT00557583 - Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults Phase 1
Terminated NCT01586325 - A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients Phase 1
Recruiting NCT02578693 - Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Recruiting NCT02583685 - Switching Regimen in Treating Cirrhotic HCV GT1b Subjects Phase 2
Completed NCT02576314 - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients Phase 3
Not yet recruiting NCT01835938 - Clinical Investigation of Erlotinib as an HCV Entry Inhibitor Phase 1/Phase 2
Completed NCT01055821 - Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients Phase 2
Completed NCT01833533 - A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection Phase 3